Generics Market Growth Will Outpace Innovative Drug Sales

8 June 1997

Worldwide, the generics drug market will grow by 14% annually betweennow and the year 2000, according to a new report from Datamonitor entitled Pharma Vitae: The Generics Intelligence Series (available through Marketletter Publications). This compares with 6% growth for innovative drugs, it adds.

The total generics market for 1996 is valued at between $30 million and $40 million (the exact definition of a generic product varies by market and so leads to an equivocal market size). As can be seen from the table below, the share of generics within various markets differs significantly.

Generic share of pharma market by value % ----------------------------------------- Country 1995 2000 *CAGR USA 11 16 7% Germany 30 40 6% UK 15 24 10% France 3 5 11% Italy 3 3 11% Spain 2 4 15% Japan 8 12 8% Source: Datamonitor * Compound annual growth rate 1995-2000 -----------------------------------------

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight